Baader Bank set a €123.00 ($143.02) price objective on Bayer (FRA:BAYN) in a report released on Thursday morning, Borsen Zeitung reports. The brokerage currently has a buy rating on the healthcare company’s stock.
BAYN has been the topic of a number of other research reports. DZ Bank reaffirmed a neutral rating on shares of Bayer in a research note on Thursday, October 31st. Barclays set a €85.00 ($98.84) price target on shares of Bayer and gave the company a buy rating in a research report on Friday, October 25th. Bank of America set a €95.00 ($110.47) price target on shares of Bayer and gave the stock a buy rating in a research note on Friday, September 13th. Goldman Sachs Group set a €77.00 ($89.53) price objective on shares of Bayer and gave the stock a buy rating in a report on Monday, November 18th. Finally, UBS Group set a €110.00 ($127.91) price objective on Bayer and gave the company a buy rating in a research report on Tuesday, November 19th. One research analyst has rated the stock with a sell rating, nine have issued a hold rating and eight have issued a buy rating to the company. The company currently has a consensus rating of Hold and a consensus price target of €78.47 ($91.24).
Shares of FRA BAYN opened at €69.18 ($80.44) on Thursday. The firm has a fifty day simple moving average of €68.70 and a two-hundred day simple moving average of €62.47. Bayer has a 12 month low of €91.58 ($106.49) and a 12 month high of €123.82 ($143.98).
Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Featured Article: Understanding Specialty Certificates of Deposit
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.